Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
This paper reports results of the DIA-DA observation program designed to study the efficacy and safety of the DPP-4 inhibitor sitagliptin added tometformin therapy in different regions of the Russian Federation. The study included 923 patients with DM2 (mean duration 4.5 years) uncontrolledby diet a...
Saved in:
Main Author: | Marina Vladimirovna Shestakova |
---|---|
Format: | article |
Language: | EN RU |
Published: |
Endocrinology Research Centre
2010
|
Subjects: | |
Online Access: | https://doaj.org/article/885e51dbaa8b4003872f07898896a2a0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
by: Alexander Sergeevich Ametov, et al.
Published: (2010) -
Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
by: Alexander Sergeevich Ametov, et al.
Published: (2010) -
Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012) -
Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL
by: Marina Vladimirovna Shestakova
Published: (2011) -
First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
by: Karina Oganesovna Galstyan, et al.
Published: (2016)